Doravirine/lamivudine/tenofovir
Combination of
DoravirineNon-nucleoside reverse transcriptase inhibitor
LamivudineNucleoside reverse transcriptase inhibitor
Tenofovir disoproxilNucleotide reverse transcriptase inhibitor
Clinical data
Trade namesDelstrigo
Other namesMK-1439A
AHFS/Drugs.comMonograph
MedlinePlusa618049
License data
Routes of
administration		By mouth
ATC code
Legal status
Legal status
Identifiers
CAS Number
KEGG

Doravirine/lamivudine/tenofovir, sold under the brand name Delstrigo, is a fixed-dose combination antiretroviral medication for the treatment of HIV/AIDS.[4][6] It contains doravirine, lamivudine, and tenofovir disoproxil.[7][6] It is taken by mouth.[4]

In the United States, it was approved by the Food and Drug Administration (FDA) for the treatment of HIV-1 infection in August 2018.[7][8][9]

References

  1. ↑ "PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION : DELSTRIGO" (PDF). Pdf.hres.ca. Retrieved 5 June 2022.
  2. ↑ "Delstrigo 100 mg /300 mg /245 mg film-coated tablets - Summary of Product Characteristics (SmPC)". Medicines.org.uk. 8 July 2020. Retrieved 1 October 2020.
  3. ↑ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 October 2023.
  4. 1 2 3 "Delstrigo- doravirine, lamivudine, and tenofovir disoproxil fumarate tablet, film coated". DailyMed. 10 October 2019. Retrieved 31 July 2020.
  5. ↑ "Delstrigo EPAR". European Medicines Agency (EMA). Retrieved 1 October 2020.
  6. 1 2 Canadian Agency for Drugs and Technologies in Health (June 2019). "Common Drug Review New Combination Product: Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate Fixed-Dose Combination (Delstrigo)". CADTH Common Drug Reviews. Ottawa (ON). PMID 31393687.
  7. 1 2 "FDA Approves Merck's Delstrigo (doravirine / lamivudine / tenofovir disoproxil fumarate), a Once-Daily Fixed-Dose Combination Tablet as a Complete Regimen and Pifeltro (doravirine), an NNRTI, Both for the Treatment of HIV-1 in Appropriate Patients" (Press release). Merck & Co. 30 August 2018.
  8. ↑ "Delstrigo approval letter" (PDF). Food and Drug Administration (FDA). 30 August 2018. Retrieved 10 September 2019.
  9. ↑ "Drug Approval Package: Pifeltro (doravirine)". U.S. Food and Drug Administration (FDA). 9 October 2018. Retrieved 22 September 2020.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.